Microvascular Angina Linked to Major Adverse CV EventsLast Updated: June 01, 2021.
TUESDAY, June 1, 2021 (HealthDay News) -- Microvascular angina (MVA) is associated with major cardiovascular events (MACE), with a comparable incidence for men and women, according to a study published online May 26 in the European Heart Journal.
Hiroaki Shimokawa, M.D., Ph.D., from the Tohoku University Graduate School of Medicine in Sendai, Japan, and colleagues prospectively evaluated the clinical characteristics of patients according to the Coronary Vasomotor Disorders International Study Group diagnostic criteria for MVA and their prognosis. The primary end point was the composite of MACE. Data were included for 686 patients with MVA registered from 14 institutes in seven countries from July 1, 2015, to Dec. 31, 2018.
The researchers found that 78 MACE occurred during a median follow-up of 398 days, with an annual incidence of 7.7 percent. No significant sex differences were seen in the incidence of MACE (6.4 percent in men and 8.6 percent in women). Hypertension and previous history of coronary artery disease, including acute coronary syndrome and stable angina pectoris, were independent predictors of MACE in a multivariable analysis. No sex or ethnic differences were identified in prognosis, although the Seattle Angina Questionnaire scores were lower for women than men.
"Our international study demonstrates the importance of coronary microvascular dysfunction in patients with MVA," Shimokawa said in a statement. "Considering the fact that coronary microvascular dysfunction is involved not only in MVA but also in other forms of cardiovascular disease, including large coronary artery disease and myocardial disease, we believe clinicians should pay closer attention to it."
Several authors disclosed financial ties to the biopharmaceutical industry.
|Previous: Arthroplasty, Arthrodesis Outcomes for Ankle Arthritis Examined||Next: Tai Chi Helps Reduce Central Obesity in Adults ≥50 Years|
Reader comments on this article are listed below. Review our comments policy.